NRBO: חוב לטווח קצר של החברה NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals is implementing software robots for clinical data analysis and automating molecule screening. The market dynamics reflected in the price action show that the separate_debt_short metric is 0.00. The business relies on outsourced production in South Korea and the US, avoiding plant ownership. The team consists of top neuropathology experts attracted by competitive compensation and a cutting-edge scientific environment.

The total volume of liabilities with a maturity of up to one year, amounting to 0.00, determines the business's financial vulnerability to rising borrowing costs and external market shocks. For NeuroBo Pharmaceuticals (NRBO), which invests in R&D to combat neurodegenerative diseases, the dynamics of short-term liabilities confirm its ability to refinance current loans without creating bankruptcy risks while developing innovative therapies.